Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H11ClN3O3S.K |
Molecular Weight | 375.872 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[NH-]S(=O)(=O)C1=CC2=C(NC(NC2=O)C3=CC=CC=C3)C=C1Cl
InChI
InChIKey=SOOGHCNPHWQISK-UHFFFAOYSA-M
InChI=1S/C14H12ClN3O3S.K/c15-10-7-11-9(6-12(10)22(16,20)21)14(19)18-13(17-11)8-4-2-1-3-5-8;/h1-7,13H,(H4,16,17,18,19,20,21);/q;+1/p-1
Molecular Formula | C14H12ClN3O3S |
Molecular Weight | 337.781 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fenquizone is the diuretic drug. The distribution of fenquizone labelled with 14C in mice was studied by means of an autoradiographic technique. High concentration of radioactivity was found in the intestine, liver, kidney, blood, myocardium and skeletal muscles in decreasing order at various times after oral administration. The labelled compound did not cross the blood-brain barrier. Fenquizone is a saluretic with a quinazolone structure which acts by blocking reabsorption of sodium in the proximal tubule and the ascending branch of the loop of Henle, as well as in the proximal section of the convoluted distal tubule. At low doses fenquizone has an hypotensive action without showing the characteristics secondary effects of diuretics so that it can be employed for long-term treatments without any risk. Fenquizone showed also a significant decrease of symptoms (headache, dizziness) due to hypertension. No undesirable side effects were observed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0035812 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6115903 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7007928
Daily dose - 20 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:55:50 UTC 2023
by
admin
on
Fri Dec 15 18:55:50 UTC 2023
|
Record UNII |
1O41UTO57H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C95125
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | |||
|
100000086966
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | |||
|
1O41UTO57H
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | |||
|
m1162
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
52246-40-9
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | |||
|
SUB02127MIG
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY | |||
|
91663265
Created by
admin on Fri Dec 15 18:55:50 UTC 2023 , Edited by admin on Fri Dec 15 18:55:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |